ProQR Therapeutics NV (MEX:PRQRN) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PRQRN ProQR Therapeutics NV MEX:PRQRN
50 GF Score
Price MXN36.00
GF Value MXN39.89
! 2 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV SpecialCharges?

Special Charges only applies to banks.

MEX:PRQRN
50GF Score
ProQR Therapeutics NV MEX:PRQRN
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of MXN36.00 is trading 9.8% below its estimated GF Value™ of MXN39.89.

Key valuation signals for MEX:PRQRN:

  • SpecialCharges:
  • GF Value™: MXN39.89 vs. price of MXN36.00 (9.8% below fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ProQR Therapeutics NV Business Description

Other Exchanges PRQR:USA0PQ:Germany
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
50GF Score

Get the complete analysis for MEX:PRQRN

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN36.00
Price
MXN39.89
GF Value